Eligible publications included clinical trials, retrospective cohorts, and translational or molecular studies that reported paired HER2 assessment in breast cancer and were interpreted according to American Society of Clinical Oncology/College of American Pathologists-aligned criteria. Here, ERBB2 is linked to breast cancer.